Chimerix (NASDAQ:CMRX) Given Buy Rating at HC Wainwright

Chimerix (NASDAQ:CMRX)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $11.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 128.26% from the stock’s previous close.

Separately, Wedbush restated an “outperform” rating and issued a $6.00 price target on shares of Chimerix in a report on Tuesday, December 10th.

Chimerix Stock Up 10.0 %

NASDAQ:CMRX traded up $0.44 during mid-day trading on Tuesday, hitting $4.82. 4,342,922 shares of the stock traded hands, compared to its average volume of 1,546,786. Chimerix has a 52 week low of $0.75 and a 52 week high of $5.15. The stock has a market capitalization of $433.42 million, a price-to-earnings ratio of -5.13 and a beta of 0.35. The firm’s 50 day moving average is $3.60 and its two-hundred day moving average is $1.85.

Insider Buying and Selling

In other news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now directly owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 20,760 shares of company stock valued at $91,175 over the last 90 days. Corporate insiders own 13.10% of the company’s stock.

Hedge Funds Weigh In On Chimerix

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC purchased a new stake in shares of Chimerix during the fourth quarter valued at about $130,000. Two Sigma Investments LP raised its stake in shares of Chimerix by 309.1% during the 4th quarter. Two Sigma Investments LP now owns 101,156 shares of the biopharmaceutical company’s stock worth $352,000 after acquiring an additional 76,430 shares in the last quarter. OMERS ADMINISTRATION Corp purchased a new stake in Chimerix during the fourth quarter valued at approximately $535,000. Millennium Management LLC boosted its stake in Chimerix by 6.8% in the fourth quarter. Millennium Management LLC now owns 2,557,530 shares of the biopharmaceutical company’s stock valued at $8,900,000 after acquiring an additional 161,795 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C purchased a new position in Chimerix in the fourth quarter worth $13,124,000. Hedge funds and other institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.